EMEA Growth & Product Launches to Support Boston Scientific Stock
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Rick Wise - Stifel David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Josh Jennings - TD Cowen Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Matt Miksic - Barclays Operator Good morning, and welcome to the Boston Scientific First Quarter 2025 Earnings Call. All participants will be in listen-only mode.
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
Boston Scientific (BSX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire
Shares of Boston Scientific (BSX) rose sharply Wednesday after the firm posted first-quarter results that topped analysts' estimates.
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.56 per share a year ago.
